Cantor Fitzgerald began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research report report published on Wednesday morning, Marketbeat reports. The firm issued an overweight rating on the stock.
Palvella Therapeutics Stock Performance
Shares of PVLA stock opened at $11.79 on Wednesday. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $22.32.
Featured Stories
- Five stocks we like better than Palvella Therapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Why Invest in High-Yield Dividend Stocks?
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- How to Invest in the FAANG Stocks
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
